Malignant Tumor Of Pancreas — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for malignant tumor of pancreas. 25 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
25
Active US patents
59/100
Avg vulnerability
$2.6B
Annual revenue covered

Originators in Malignant Tumor Of Pancreas

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca 25 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating malignant tumor of pancreas. Each bar = one year. Y-axis scaled to peak year (12 patents).

7
27
1
28
12
29
3
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lynparza
olaparib
 AstraZeneca 25 59 $2.6B 2027-08-12

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8143241 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8071579 Lynparza method of use 75 2027-08-12
8143241 Lynparza method of use 75 2027-08-12
8071579 Lynparza method of use 75 2027-08-12
11970530 Lynparza method of use 75 2041-10-25
11970530 Lynparza method of use 75 2041-10-25
8859562 Lynparza method of use 68 2031-08-04
8859562 Lynparza method of use 68 2031-08-04
8859562 Lynparza method of use 68 2031-08-04

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8247416 Lynparza composition of matter 17 2028-09-24
7449464 Lynparza composition of matter 17 2027-09-08
7449464 Lynparza composition of matter 17 2027-09-08
8475842 Lynparza formulation 48 2029-12-31
8475842 Lynparza formulation 48 2029-12-31
11633396 Lynparza formulation 56 2029-10-07
11633396 Lynparza formulation 56 2029-10-07
11975001 Lynparza formulation 61 2029-10-07
12178816 Lynparza formulation 61 2029-10-07
12048695 Lynparza formulation 61 2029-10-07

Related